ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Smartphone-based patient-reported outcome of acute phase reaction after zoledronic acid infusion and prediction algorithm: a multicenter, prospective cohort study.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute phase reaction (APR) after zoledronic acid infusion impairs adherence and treatment outcomes. Using smartphone-based ePRO monitoring, we developed a simple prediction model for severe APR incorporating age, sex, and day-1 symptoms. This algorithm showed good discrimination and may enable early identification and personalized prevention of severe APR. PURPOSE: Zoledronic acid (ZOL) is an effective antiresorptive therapy for osteoporosis, but acute phase reaction (APR) after initial infusion may impair adherence and outcomes. Identifying individuals at high risk for severe APR is essential for personalized prevention.
methodsThis multicenter, prospective observational study collected electronic patient-reported outcome (ePRO) data via a smartphone application after a single 5-mg ZOL infusion. Adults aged ≥ 19 years reported the severity of nine APR symptoms daily for four days using a 5-point scale. Daily scores were summed to calculate a total APR score. Severity was categorized as mild-to-moderate or severe based on the median of total APR score. A prediction algorithm for severe APR was developed using age, sex, and day-1 symptoms.
resultsAmong 685 participants (mean age 70.6 years; 83.7% women), 222 (32.4%) experienced APR, and 118 (17.2%) developed severe APR. APR scores peaked on day 2 and declined by day 4. Severe APR showed earlier onset, longer duration, and greater symptom burden than mild-to-moderate APR. Younger age and female sex were associated with severe APR. Five day-1 symptoms (myalgia, arthralgia, chills, headache, and back pain) were identified as core predictors. A compact model incorporating age, sex, and the number of day-1 core symptoms demonstrated good discrimination for severe APR (AUROC 0.81).
conclusionSmartphone-based ePRO effectively captured APR severity following ZOL. A simple clinical algorithm using age, sex, and day-1 symptoms accurately identified individuals at high risk for severe APR, enabling personalized preventive strategies.
Indexed as
Identifiers
42545373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.